Siemens may sell dental businesses
German industrial conglomerate Siemens AG is looking to divest its dental business, but plans to retain the bulk of its Medical Engineering Group, contrary to rumors that have surfaced in the European press recently.Siemens reported April 21 that it is
German industrial conglomerate Siemens AG is looking to divest its dental business, but plans to retain the bulk of its Medical Engineering Group, contrary to rumors that have surfaced in the European press recently.
Siemens reported April 21 that it is looking for a merger partner or acquirer for its Dental Systems division in Bensheim, Germany, and Pelton & Crane subsidiary in Charlotte, NC. Siemens said the move was part of the group's ongoing effort to improve its competitiveness and cost structure (SCAN 3/19/97).
The company emphasized that it does not intend to divest the rest of Medical Engineering, however.
"There is no reason for deleting Medical Engineering from our core businesses," said Heinrich von Pierer, chairman of Siemens AG. "It is obvious that our medical portfolios...are subject to permanent development."
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can a Six-Minute MRI Facilitate Detection of Multiple Sclerosis?
May 23rd 2025Recognition of the central vein sign with a six-minute MRI demonstrated comparable sensitivity for multiple sclerosis (MS) detection in comparison to oligoclonal band (OCB) assessment, which requires lumbar puncture, according to newly published research.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
